By Sneha S K April 2 (Reuters) - Immunovant said on Thursday that its therapy failed to reduce eye bulging when tested in ...

By Siddhi Mahatole March 30 (Reuters) - Viridian Therapeutics shares slumped 34% to an eight-month low on Monday after its ...

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that ...

Researchers have successfully used a new robot system to improve treatment for debilitating eye disease. Researchers from King's, with doctors at King's College Hospital NHS Foundation Trust, have ...

Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD; explore the current treatment landscape of dry eye disease. This is a video synopsis/summary of a Stakeholder Summit involving: Ryan Haumschild, ...

Once relatively rare, dry eye disease (DED) is now considered one of the most common — and annoying — eye conditions. Here’s what you need to know about determining if you have it, identifying the ...

For patients with mild dry eye syndrome (DES), aqueous or lipid enhancement of the tear film with topical agents is the appropriate first-line therapy. These include emulsions, gels and ointments ...

FRESNO, Calif. (KFSN) -- A Fresno eye doctor is the first in the Valley to offer a groundbreaking light-based treatment for dry eye disease. According to doctors, dry eye disease is a common condition ...

More than 360 million people around the world suffer from dry eye disease, which is characterized by chronically red, scratchy or irritated eyes. blackday - stock.adobe.com Dry eye disease is no ...